NRX Pharmaceuticals, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -447.3% | -447.3% | -284.3% |
| FY2022 | -536.6% | -388.6% | -154.0% |
| FY2023 | 257.0% | 1,172.2% | -412.2% |
| FY2024 | 108.2% | 108.2% | -688.2% |
| FY2025 | 179.6% | 179.6% | -220.9% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -447.3% | -447.3% | -284.3% |
| FY2022 | -536.6% | -388.6% | -154.0% |
| FY2023 | 257.0% | 1,172.2% | -412.2% |
| FY2024 | 108.2% | 108.2% | -688.2% |
| FY2025 | 179.6% | 179.6% | -220.9% |